tbResList Print — ISO, IH Isorhamnetin

Filters: qv=519, qv2=%, rfv=%

Product

ISO, IH Isorhamnetin
Description:
<p><b>Isorhamnetin</b> — A naturally occurring O-methylated flavonol and 3′-O-methyl derivative of quercetin (C16H12O7; molecular weight 316.26 g/mol). Classified as a polyphenolic flavonoid compound, abbreviated ISO or IH. Found in sea buckthorn (Hippophae rhamnoides), onions, Ginkgo biloba, and various medicinal plants, and also formed through metabolic methylation of quercetin. It exhibits antiproliferative, pro-apoptotic, anti-inflammatory, antioxidant, and antimetastatic activities in experimental models. Its anticancer potential is supported by cell culture and animal studies, particularly involving PI3K/AKT/mTOR signaling and mitochondrial apoptosis, but clinical anticancer efficacy in humans remains unestablished.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li><b>PI3K/AKT/mTOR suppression:</b> ↓ PI3K/AKT/mTOR phosphorylation and downstream growth signaling, reducing proliferation and survival in prostate, colorectal, breast, and other cancer models.</li>
<li><b>Mitochondrial apoptosis:</b> ↑ Bax/Bcl-2 ratio, mitochondrial membrane dysfunction, cytochrome c release, and caspase-9/3 activation, promoting intrinsic apoptotic death.</li>
<li><b>Cell-cycle arrest:</b> Alters cyclins and cell-cycle regulators, producing G2/M or G0/G1 arrest depending on cancer model and exposure.</li>
<li><b>MAPK/MEK/ERK modulation:</b> ↓ MEK/ERK phosphorylation in selected breast cancer models, reinforcing suppression of proliferative and survival signaling.</li>
<li><b>NF-κB inhibition:</b> ↓ NF-κB activation and downstream inflammatory and anti-apoptotic gene expression, contributing to apoptosis and experimental chemotherapy sensitization.</li>
<li><b>Invasion and metastasis suppression:</b> ↓ MMP-2/MMP-9, migration, invasion, and epithelial–mesenchymal transition signaling in responsive tumor models.</li>
<li><b>ROS/HIF-1α regulation:</b> ↓ ROS-dependent HIF-1α stabilization, hypoxia-responsive transcription, and associated metabolic and invasive signaling in some colorectal cancer models. Oxidative effects are context-dependent.</li>
<li><b>Glycolysis suppression:</b> ↓ SRC/PI3K/AKT-associated glycolytic signaling, glucose uptake, lactate production, and glycolytic enzyme expression in experimental bladder cancer cells.</li>
<li><b>Chemosensitization:</b> Enhances experimentally observed responses to capecitabine, cisplatin, and carboplatin through survival-pathway suppression and increased apoptosis. Human clinical benefit remains unproven.</li>
<li><b>Normal-cell cytoprotection:</b> Antioxidant, anti-inflammatory, and metabolic protective effects, including experimental attenuation of cisplatin-associated renal injury.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Oral exposure is limited by low aqueous solubility, intestinal absorption constraints, and extensive glucuronidation and sulfation. Isorhamnetin is also a circulating metabolite of dietary quercetin. In a human onion-feeding study, isorhamnetin-3-glucuronide reached approximately 0.11 µM peak plasma concentration, with an elimination half-life of approximately 5.34 hours. These measurements concern the conjugated metabolite, not free isorhamnetin. Nanoformulations and lipid-based carriers may improve exposure experimentally, but an established anticancer oral dose and formulation do not exist.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer experiments employ approximately 5–100 µM unconjugated isorhamnetin, substantially above the approximately 0.1 µM circulating conjugated metabolite observed following dietary flavonol intake. Free systemic isorhamnetin concentrations after ordinary dietary exposure are generally much lower than typical experimental anticancer concentrations. Direct comparison is complicated by metabolite activity, tissue distribution, and formulation differences. Reproducing cell-culture effects with conventional oral intake is not established.</p>

<p><b>Clinical evidence status:</b> Preclinical anticancer evidence from multiple cancer cell lines and selected animal models. Human dietary pharmacokinetic data are available, but no established randomized controlled trial evidence demonstrates anticancer efficacy of isolated isorhamnetin. Investigational adjunct potential only. Not an approved cancer therapy. Clinical dosing, long-term safety at pharmacological doses, drug interactions, and therapeutic efficacy remain insufficiently characterized.</p>



<h3>Isorhamnetin — Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PI3K / AKT / mTOR</td>
<td>↓ p-PI3K, p-AKT, p-mTOR, p70S6K</td>
<td>↔ / context-dependent</td>
<td>R/G</td>
<td>↓ Proliferation and survival</td>
<td>Core mechanism supported in colorectal, breast, and androgen-independent prostate cancer models.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial Apoptosis</td>
<td>↑ Bax, cytochrome c, caspase-9/3; ↓ Bcl-2, mitochondrial membrane potential</td>
<td>↔ / cytoprotection (model-dependent)</td>
<td>R/G</td>
<td>↑ Intrinsic apoptosis</td>
<td>Prominent in lung, prostate, and breast cancer. Selectivity is model-dependent and not established clinically.</td>
</tr>
<tr>
<td>3</td>
<td>Cell-Cycle Regulation</td>
<td>↑ G2/M or G0/G1 arrest; altered cyclins and CDKs</td>
<td>↔ / unknown</td>
<td>G</td>
<td>↓ Cell division</td>
<td>Arrest phase varies by cell line. G2/M arrest demonstrated in colorectal cancer models.</td>
</tr>
<tr>
<td>4</td>
<td>MEK / ERK / MAPK</td>
<td>↓ p-MEK, p-ERK</td>
<td>↔ / context-dependent</td>
<td>R/G</td>
<td>↓ Growth signaling</td>
<td>Demonstrated in breast cancer; not uniformly inhibited across all tissues or MAPK branches.</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB / Inflammatory Survival</td>
<td>↓ NF-κB activation, anti-apoptotic signaling</td>
<td>↓ Inflammatory signaling (model-dependent)</td>
<td>R/G</td>
<td>↓ Survival and inflammatory promotion</td>
<td>Important in gastric cancer capecitabine combination models and experimental melanoma.</td>
</tr>
<tr>
<td>6</td>
<td>MMP / EMT / Invasion</td>
<td>↓ MMP-2, MMP-9, migration, invasion; ↑ epithelial phenotype</td>
<td>↔ / unknown</td>
<td>G</td>
<td>↓ Metastatic behavior</td>
<td>Antimigratory effects demonstrated experimentally; clinical metastasis prevention unproven.</td>
</tr>
<tr>
<td>7</td>
<td>ROS / HIF-1α</td>
<td>↓ ROS-dependent HIF-1α accumulation (context-dependent)</td>
<td>↓ Oxidative injury (model-dependent)</td>
<td>R/G</td>
<td>↓ Hypoxic stress signaling</td>
<td>Antioxidant suppression of HIF-1α demonstrated in colorectal cells. Other tumor models can exhibit pro-oxidative apoptotic responses.</td>
</tr>
<tr>
<td>8</td>
<td>SRC / Glycolysis</td>
<td>↓ p-SRC, HK2, GLUT1, PFKFB3, glucose uptake, lactate</td>
<td>Unknown</td>
<td>R/G</td>
<td>↓ Glycolytic metabolism</td>
<td>2026 bladder cancer cell study identified SRC-associated metabolic suppression. Requires broader in-vivo validation.</td>
</tr>
<tr>
<td>9</td>
<td>Autophagy / Apoptosis Balance</td>
<td>↑ Autophagy and apoptosis in some models</td>
<td>Context-dependent</td>
<td>G</td>
<td>Variable cytoprotective autophagy</td>
<td>Autophagy inhibition enhanced isorhamnetin-induced apoptosis in A549 lung cancer models; autophagy is not uniformly tumor-suppressive.</td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization</td>
<td>↑ Capecitabine or platinum-associated apoptosis (model-dependent)</td>
<td>Potential protection (model-dependent)</td>
<td>G</td>
<td>↑ Experimental drug response</td>
<td>Capecitabine combination supported by gastric cancer xenograft data; platinum combinations reported in A549 cells. No clinical validation.</td>
</tr>
<tr>
<td>11</td>
<td>Normal-Tissue Oxidative Protection</td>
<td>↔ / model-dependent</td>
<td>↓ Oxidative stress and renal injury; ↑ fatty acid oxidation (model-dependent)</td>
<td>G</td>
<td>Potential tissue protection</td>
<td>Preclinical cisplatin nephrotoxicity evidence. Does not establish preservation of chemotherapy efficacy in patients.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Effective experimental concentrations frequently 5–100 µM</td>
<td>Human high-dose safety uncertain</td>
<td>G</td>
<td>Limited systemic exposure and clinical evidence</td>
<td>Extensive metabolism, low free-compound exposure, formulation dependence, and absence of validated human anticancer dosing. Dietary isorhamnetin-3-glucuronide Cmax approximately 0.11 µM.</td>
</tr>
</tbody>
</table>
<p>TSF: P: 0–30 min&nbsp;&nbsp;&nbsp; R: 30 min–3 hr&nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>




Pathway results for Effect on Cancer / Diseased Cells

NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

GSTs↓, 1,   ROS↓, 1,   ROS↑, 5,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↑, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 2,   CAIX/CA9↓, 3,   ECAR↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   PDK1 / PDPK1↓, 1,   PFKFB3↓, 1,   PFKFB4?, 1,   TumCM/A↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 7,   BAX↑, 5,   Bcl-2↓, 4,   Casp↑, 1,   Casp3↑, 4,   cl‑Casp3↑, 2,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 5,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 8,   p‑Akt↓, 1,   ERK↓, 1,   MAPK↓, 3,   MEK↓, 1,   mTOR↓, 6,   PI3K↓, 6,   PTEN↓, 2,   p‑Src↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 4,   PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↑, 1,   CycB/CCNB1↑, 1,   CycB/CCNB1↓, 1,   P21↑, 1,   TumCCA↑, 6,   TumCCA?, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 2,   TumCG↑, 1,   TumCP↓, 12,  

Migration(tgid=13) ⓘ

E-cadherin↑, 3,   EMT↓, 3,   MET↑, 2,   MMP2↓, 4,   MMP9↓, 4,   MMPs↓, 2,   N-cadherin↓, 3,   Snail↓, 1,   TumCA↓, 1,   TumCI?, 1,   TumCI↓, 2,   TumCMig?, 1,   TumCMig↓, 5,   uPA↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 2,   MMP↓, 4,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD155↓, 1,   COX2/PTGS2↓, 1,   Eos↑, 1,   Imm↑, 1,   Neut↑, 1,   NF-kB↓, 3,   TIGIT↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARγ↓, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↓, 1,   ChemoSen↑, 3,   CYP1A1↓, 1,   CYP1B1↓, 1,   Dose↝, 1,   MDR1↓, 1,   MRP1/ABCC1↓, 1,   MRP5↓, 1,   P-gp/ABCB1↓, 1,   selectivity↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

LDH↓, 2,   Tumccf↓, 2,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 2,   radioP↑, 1,   RenoP↑, 2,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 100

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   antiOx↓, 1,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   NRF2↑, 2,   ROS↓, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↓, 1,   CPT1A↑, 1,   FAO↑, 1,   lipidLev↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Ferroptosis↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 2,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1β↓, 1,   Inflam↓, 4,   NK cell↑, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARα↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Half-Life↝, 1,  

Functional Outcomes(tgid=23) ⓘ

antiCG↑, 1,   AntiTum↑, 1,   cardioP↑, 2,   chemoP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 2,   RenoP↑, 2,   Stroke↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 2,   Bacteria↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 39

Research papers

Year Title Authors PMID Link Flag
2026Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axisFeng Haiya—https://link.springer.com/article/10.1007/s00432-026-06577-80
2026Isorhamnetin inhibits migration and promotes apoptosis via modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 axis in 4T1 breast cancer cellsFei ChenPMC13189752https://pmc.ncbi.nlm.nih.gov/articles/PMC13189752/0
2025Isorhamnetin Modulates Drug-Resistance-Related Biomarkers in Colon Cancer CellsNikola Radenković—https://www.mdpi.com/1422-0067/26/13/62080
2025Progress in the antitumor molecular mechanisms of IsorhamnetinAnyang LiuPMC12830526https://pmc.ncbi.nlm.nih.gov/articles/PMC12830526/0
2025Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven DeliveryJuie Nahushkumar RanaPMC12347436https://pmc.ncbi.nlm.nih.gov/articles/PMC12347436/0
2025Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and ApplicationsChen MeiPMC12158059https://pmc.ncbi.nlm.nih.gov/articles/PMC12158059/0
2024Isorhamnetin: what is the in vitro evidence for its antitumor potential and beyond?Jiaming LeiPMC11033395https://pmc.ncbi.nlm.nih.gov/articles/PMC11033395/0
2023Isorhamnetin alleviates cisplatin-induced acute kidney injury via enhancing fatty acid oxidationLingkun Wang38101584https://pubmed.ncbi.nlm.nih.gov/38101584/0
2020Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathwayFangzhen CaiPMC7080645https://pmc.ncbi.nlm.nih.gov/articles/PMC7080645/0
2020Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF- κ B PathwaysRan DuanPMC7225865https://pmc.ncbi.nlm.nih.gov/articles/PMC7225865/0
2016Isorhamnetin Inhibits Reactive Oxygen Species-Dependent Hypoxia Inducible Factor (HIF)-1α AccumulationSuho Seo27803454https://pubmed.ncbi.nlm.nih.gov/27803454/0
2015Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancerKanjoormana A Manu25827070https://pubmed.ncbi.nlm.nih.gov/25827070/0
2015Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC)Bao-Yi ZhangPMC4348816https://pmc.ncbi.nlm.nih.gov/articles/PMC4348816/0
2015Autophagy inhibition enhances isorhamnetin‑induced mitochondria‑dependent apoptosis in non‑small cell lung cancer cellsYUSHU RUANPMC4581743https://pmc.ncbi.nlm.nih.gov/articles/PMC4581743/0
2015Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen‑activated protein kinase kinase signaling pathwaysSHAN HUPMC4626180https://pmc.ncbi.nlm.nih.gov/articles/PMC4626180/0
2014Isorhamnetin suppresses colon cancer cell growth through the PI3K‑Akt‑mTOR pathwayChuan Li24398569https://pubmed.ncbi.nlm.nih.gov/24398569/0
2006Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onionsWilliam Mullen16869998https://pubmed.ncbi.nlm.nih.gov/16869998/0